Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Central retinal vein

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    49 result(s) found for: Central retinal vein. Displaying page 2 of 3.
    « Previous 1  2  3  Next»
    EudraCT Number: 2016-004648-12 Sponsor Protocol Number: CLS1003-301 Start Date*: 2018-01-15
    Sponsor Name:Clearside Biomedical, Inc.
    Full Title: SAPPHIRE: A RANDOMIZED, MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN CONJUNCTION WITH INTRAVITREAL AFLIBERCEPT IN SUBJECTS WITH RETINAL VEIN OCCLUSION
    Medical condition: Retinal Vein Occlusion
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Completed) DE (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) PT (Completed) DK (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001842-33 Sponsor Protocol Number: CRTH258C2301 Start Date*: 2019-06-14
    Sponsor Name:Novartis Pharma AG
    Full Title: An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multi center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment du...
    Medical condition: Branch retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001047-21 Sponsor Protocol Number: 690110 Start Date*: 2014-06-09
    Sponsor Name:Sankt Eriks Eye Hospital
    Full Title: Randomized trial comparing injection frequency between Aflibercept and Ranibizumab in patients with Central Retinal Vein Occlusion with a treat and extent algorithm
    Medical condition: Central retinal vein occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005045-13 Sponsor Protocol Number: CRFB002EDE20 Start Date*: 2012-04-26
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open-label, multi-center, 6-month extension study comparing the long-term efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal implan...
    Medical condition: visual impairment due to macular edema following retinal vein occlusion (branch or central)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10054467 Macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001727-19 Sponsor Protocol Number: 45/2006/U/Sper Start Date*: 2006-10-03
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Triamcinolone Acetonide Intravitreal Injection for the treatment for exudative maculopathy
    Medical condition: exudative maculopathy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038862 Retinal exudates LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005468-25 Sponsor Protocol Number: CRFB002ANO01 Start Date*: 2007-01-24
    Sponsor Name:Retinaklinikken Aleris
    Full Title: A randomized study comparing the safety and efficacy of ranibizumab (Lucentis ®) to sham in patients with macular edema secondary to central retinal vein occlusion (CRVO).
    Medical condition: Macular edema secondary to central retinal vein occlusion (CRVO)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10054467 Macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005449-18 Sponsor Protocol Number: MMT_2020_33 Start Date*: 2021-03-08
    Sponsor Name:Hôpital Fondation A. de Rothschild / Service de recherche clinique
    Full Title: Spontaneous retinal artery pulses as a prognostic determinant of central retinal vein occlusions in patients with and without intravitreal aflibercept injections.
    Medical condition: Central retinal vein occlusions
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001678-25 Sponsor Protocol Number: 138/06 Start Date*: 2006-02-16
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Macular structure and function after intravitreal injection of bevacizumab for vascular retinopathy a interventional study.
    Medical condition: vascular retinopathy
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038923 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000975-21 Sponsor Protocol Number: RET-AFLI-2014-01 Start Date*: 2014-06-16
    Sponsor Name:Fundación Retinaplus +
    Full Title: A phase IV study to evaluate the effectiveness of aflibercept in naive patients with macular edema secondary to Central Retinal Vein Occlusion (CRVO) on an individualized Treat and Extend regimen. ...
    Medical condition: Macular edema secondary to central retinal vein occlusion.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003288-21 Sponsor Protocol Number: EURIVAT2 Start Date*: 2005-09-28
    Sponsor Name:Dept. of Ophthalmology, Medical University of Vienna
    Full Title: INTRAOCULAR BEVACIZUMAB (AVASTIN™) FOR CENTRAL AND BRANCH RETINAL VEIN OCCLUSION STUDY
    Medical condition: CENTRAL AND BRANCH RETINAL VEIN OCCLUSION
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002350-31 Sponsor Protocol Number: CRFB002E2401 Start Date*: 2012-02-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5-mg ranibizumab in...
    Medical condition: visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10007972 Central retinal vein occlusion LLT
    14.1 10015919 - Eye disorders 10025415 Macular oedema PT
    14.1 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) SE (Completed) HU (Completed) AT (Completed) ES (Completed) CZ (Completed) SK (Completed) GR (Completed) PT (Completed) NL (Completed) PL (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-002826-31 Sponsor Protocol Number: V1 Start Date*: 2007-11-09
    Sponsor Name:Medical University of Vienna
    Full Title: Response of retinal vessels to anti vascular endothelial growth factor (VEGF) treatment in patients with branch retinal vein occlusion (BRVO)
    Medical condition: Cystoid macular oedema due to branch retinal vein occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001020-38 Sponsor Protocol Number: CRFB002EDE18 Start Date*: 2011-06-24
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal imp...
    Medical condition: visual impairment due to macular edema following central retinal vein occlusion (CRVO)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10054467 Macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-001143-12 Sponsor Protocol Number: 11-EI-0264 Start Date*: 2018-01-09
    Sponsor Name:The National Eye Institute
    Full Title: A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Central Retinal Vein Occlusions
    Medical condition: Central Retinal Vein Occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-006131-53 Sponsor Protocol Number: AU-06104G Start Date*: 2007-08-02
    Sponsor Name:Society (institute) for clinical research
    Full Title: Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study
    Medical condition: Macular edema secondary to branch retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025415 Macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001179-21 Sponsor Protocol Number: 11-EI-0263 Start Date*: 2018-01-17
    Sponsor Name:The National Eye Institute
    Full Title: A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Branch Retinal Vein Occlusions
    Medical condition: Branch Retinal Vein Occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-006265-93 Sponsor Protocol Number: AVO1 Start Date*: 2009-03-11
    Sponsor Name:St Eriks Eye Hospital
    Full Title: A prospective, randomized, masked and controlled trial of intravitreal bevacizumab (Avastin®) for central retinal vein occlusion (CRVO).
    Medical condition: Central retinal vein occlusion (CRVO) is a sight-threatening ocular condition without efficient treatment.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023110-30 Sponsor Protocol Number: Octome Start Date*: 2011-04-11
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: An exploratory phase III prospective open-label clinical study on monthly OCT monitoring of the effects of Ozurdex for macular oedema related to retinal vascular diseases
    Medical condition: Macular oedema related to retinal vascular diseases
    Disease: Version SOC Term Classification Code Term Level
    10025415 Macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001019-30 Sponsor Protocol Number: CRFB002EDE17 Start Date*: 2011-06-01
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal imp...
    Medical condition: visual impairment due to macular edema following branch retinal vein occlusion (BRVO)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10054467 Macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002089-37 Sponsor Protocol Number: CLS1003-302 Start Date*: 2018-09-27
    Sponsor Name:Clearside Biomedical, Inc.
    Full Title: TOPAZ: A RANDOMIZED, MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN COMBINATION WITH AN INTRAVITREAL ANTI-VEGF AGENT IN SUBJECTS WITH RETINAL VEIN OCCLUSION
    Medical condition: Retinal Vein Occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Completed) EE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 01:18:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA